Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Getinge, Audiocast, Q1'26

By Inderes4/21/2026, 11:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:02 - 07:34

Thanks and welcome, everyone. Thanks for joining the call today. As mentioned in the intro here, it's me and our CFO, Agneta Palmér. We are with you today. And in today's conference, we'll go through performance and some of the highlights in the first quarter of 2026 before opening up for a Q&A. So let's move directly to page number two, please. And I'd like to start by looking at the development of some of our strategic KPIs. And as you can see here, it's evident that we continue to clearly track in line with plan to increase the share of sales from recurring revenue and also accelerating the share of sales from higher margin products. For example, our ECLS offering, our consumables in infection control, and our bioreactors within the sterile transfer product category. This is all supported, of course, by solid and effective quality processes. And if we look at the specifics here, you can see that sales from recurring revenue continue to make up two thirds and high margin products closing in on about 70% right now. When it comes to quality, the number of field actions in relation to sales has decreased significantly, and we see this positive trend sequentially continue also into the beginning of 2026. And these improvements, we always act in line with responsible leverage and an attractive long-term return on invested capital. We can move to page number three, please. So if we then look at some of the key takeaways from the first quarter, we managed to beat last year's record quarter and grow top line organically. Net sales grew by 0.8% organically, with positive developments specifically in Life Science and in Surgical Workflows. And on the order intake front, we saw an organic increase of 3.9%. When it comes to our adjusted gross and EBITDA margins, they were down in the quarter, mainly due to strong headwinds from currency and tariffs, and adjusting for the 226 MSEK in currency and tariff headwinds in the quarter, the EBITA margin was about 50 basis points higher than last year's Q1. So the conclusion from that is that the underlying performance in our business continues to be strong, and it's developing according to the plans. The long-term plans that we have laid out, we also have a strong cash flow and continue to have a solid financial position. So our financial leverage is at 1.5 and well below the two and a half times EBITDA that we have as an internal threshold. We can then move over to page number four and some of the key events during the quarter. And if we start with our product offering and our customers, I think one situation that is, of course, evolving on a daily basis is the situation in Middle East, and we continue to monitor this closely. Our first priority is, of course, to tend to our employees in the region and continue to support our customers. And if you look at the region as such, it makes up about 2% of our sales. Of that, Saudi Arabia accounts for half. So and so forth. The impact on top line and on cost has been very limited for us. To our Life Science customers. We launched a new steam sterilizer dedicated to larger items used for labs and for research applications. And when it comes to the sustainability and quality perspective, I'm very happy to see that we got the CE approval for Cardiohelp II in the quarter. And I'll talk more about that on the coming slide here. In addition to this, we have in our implant business received EU MDR certificate for the Intergard Synergy, which is a vascular graft with an antimicrobial coating to minimize the risk of infections. Furthermore, in the quarter, we released our Annual Report for 2025, including our sustainability statement. And. The annual report provides a lot of good information on Getinge. So I encourage you to have a look at this if you haven't done so already. We can then move to page number five, please. So just wanted to elaborate a moment on the positive news about the CE approval for Cardiohelp II. And just to remind everybody, this is a market segment where we are already the global market leader within ECLS therapy, thanks to our strong existing portfolio. With the launch of Cardiohelp II, we now become even more relevant for our customers. And some of the system's key features are that it's even more lightweight and transportable, meaning that it can be used for both in-hospital and intrahospital use. It also has an attachable gas blender as an option, which is something that is highly appreciated by our customers. And from an interface standpoint, we have an interface now that is even easier for users to operate. It includes these. It also features several smart monitoring functionalities for better decision support for our customers. We have initiated a limited market release now, in the beginning of the second quarter to a handful of customers, and very happy to see how positive the reception from our customers has been for this important product. The plan now is to do a full CE market release at the beginning of the third quarter, and when it comes to the important US market, the plan is still to make the submission of the Cardiohelp II system, including our HLS Advanced consumables, in the second half of this year. We can then move to page number six and talk about the top line for a moment. So overall, we had a solid top line performance in Life Science and in Surgical Workflows. And when it comes to order intake for the group, we grew 3.9% organically. The order intake for Acute Care Therapies decreased mainly due to the temporarily high comparative figures in ventilation, where one competitor last year drastically exited the market. So we were very successful in capturing some of that market share. At the same time, we saw really good growth when it comes to ECLS consumables across the board. And this is, as you know, one of our key categories in Life Science; the organic order intake increased. Order intake increased in the quarter, for example, because of an anticipated improvement from low levels that we've seen in Bio-Processing for quite some time. And this is something that it's good to see. Some of the momentum. Surgical Workflows grew double digit in the quarter, mainly on the back of the strong development across all our product areas, which is also encouraging to see that Net sales were there. We had growth of 0.8% organically for Acute Care Therapies. Organic net sales decreased mainly on the back of last year's consolidation in the ventilation market that I just mentioned. In Life Science, they had a really strong quarter in terms of deliveries, and they grew organic net sales in all product areas. BetaBags for sterile transfer continues to show significant traction and momentum in Surgical Workflows. The organic net sales increased primarily thanks to growth in infection control, consumables within service, and within our operating table category. With that, we can move over to page number seven. And I hand over to you, Agneta, for a moment.

Agneta Palmér
07:34 - 10:12

Okay. Thank you. Matthias. So overall, the headwind from tariffs and currency continued in the first quarter. Even so, we managed to hold up margins thanks to continued pricing and productivity. Starting with adjusted gross profit for the group, adjusted gross profit amounted to 3,828 million SEK in the quarter, heavily impacted by currency and tariffs. Adjusted gross margin was down by 0.7 percentage points in total in spite of healthy contribution from price and mix. If we then look at Adjusted EBITDA, adjusted for currency, Adjusted Gross Profit's effect on the EBITDA margin was plus 0.3 percentage points, while OPEX, also adjusted for currency, had a negative impact on the margin of about minus 1 percentage point in the quarter, and FX impacted the margin by -0.3 percentage points. So all in all, this resulted in an adjusted EBITDA of 824 million and a margin of 11.1%. Let's then move to page eight, please. And here we can clearly state that we remain in a solid financial position. Free cash flow amounted to 842 million in the quarter compared with last year. Free cash flow was impacted by improved operating profit and changes in working capital. Working capital days continue to be well below 100. We are now at roughly 90 days – on operating return on invested capital. We are at 11.4% on a rolling 12-month basis, which is well above the cost of capital. At the end of Q1, net debt decreased to 9.3 billion SEK. If we adjust for pension liabilities, we are now at 7 billion SEK. This brings us to a leverage of 1.5 times adjusted EBITDA, which is well below the 2.5 that we have set as an internal threshold. If we adjust for pension liabilities, leverage is at 1.1 times adjusted EBITDA. Cash amounted to approximately 4 billion SEK at the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's now move to page nine, please. And back to you, Mattias.

Mattias Perjos
10:13 - 16:03

Okay, great. Thank you. Agneta. Just a moment then to focus on the impact from tariffs. Tariffs and FX in the quarter. So this was in total a drag on Adjusted EBITA in Q1 of more than 200 million SEK. So 226 million altogether, tariffs made up just over 100 million SEK of that. And if we exclude the impact of tariffs and currency, our adjusted EBITA margin in Q1 would have been 12.6%. As you can see, showing then an underlying improvement as tariffs were first implemented in Q2 of 2025, then we expect the year-on-year comparison to be a little bit cleaner from Q2 and onwards if tariff levels remain. And that's, of course, something we'll continue to update you on. We can then move over to page number ten, please. So I want to talk a little bit more about the long term as well. So zooming out and returning to what we said at the Capital Market Update that we had in May of 2024. There we talked about an Adjusted EBITA margin of 16 to 19% by the end of 2028. And I think we're on a steady path of reaching that. Despite the headwind factors we were not aware of when we announced this target. The main drivers which will enable this are growth, mix, and productivity, with the growth aspect encompassing regulatory approvals and key strategic product launches such as Cardiohelp II that we've talked about here, as well as launching our low-temp sterilization in the US, and having the sales restrictions removed for CardioSave in our intra-aortic balloon pump business. It's just to mention a few factors here; specifically when it comes to CardioSave, I'm happy to say that we, at the end of last week, got the release for sales in key countries in line with the plan for Q2. We also expect that the investment fatigue that we've seen in the pharma industry will improve. And some of the decision decision anxiety that we've seen in the last year will go away here as well. We will also, in addition to this, get our share of the announced US investments and benefit from the recovery in Bio-Processing. And of course, we will also continue our diligent and successful work with realizing price increases annually. When it comes to mix, we have been successful in our strategic intent to steer our business towards a continued rotation to high margin products and consumables, and if possible, we prefer to have products made up of a competent hardware with captive consumables attached to it, similar to what we have in our ECLS offering with Cardiohelp II and HLS, and in the sterile transfer offering with alpha ports. Driving the consumption of beta bags. Our strong R&D and innovation pipeline is, of course, set to support this. When it comes to productivity. Here, we've already done a lot in different parts of the business, and we are still excited that there remain quite a few opportunities across the business as well. One thing to mention is the heightened, extraordinary quality cost connected to the product uplift of Cardiosave and Cardiohelp that is expected now to go down in the second half of 2026. And that will be on a lower level in 2027 and 2028. Furthermore, we will of course continue with our production excellence effort, where we also have some very tangible, measurable benefits that will help us further optimize our supply chain and maintain an overall tight cost control across the company. So this all supports our assessment that our target for 2028 is still within good reach. Then we can move over to page 11 please. For the remainder of 2026, we confirm the financial outlook for 2026. As we all know, there are some geopolitical uncertainties that we need to navigate, but based on the underlying demand and the dialogue that we have with our customers on a daily basis, our expectation remains for an organic net sales growth in the range of 3 to 5%, adjusted for the phase out of the Surgical Perfusion product category. Surgical Perfusion is still expected to have some net sales in 2026, but declining from about 250 million last year to 50 million this year. We can then move to page 13, please. So in terms of summarizing here, the key takeaways from the first quarter, we did achieve organic growth in our top line despite the record quarter last year. Tariffs and FX continue to be a significant headwind. But our underlying performance is improving. And our cash flow was really strong in the quarter. And our financial position remains solid as well. For 2026, we reiterate our guidance for an organic net sales growth of 3 to 5%, adjusted for the phase out of the Surgical Perfusion. And when it comes to our priorities for 2026, you've heard them before. We are focused on addressing the remaining challenges when it comes to quality remediation in Acute Care Therapies, focusing on sustainable productivity improvements and cost consciousness when it comes to navigating the geopolitical uncertainty, and also addressing the impact from tariffs. And most importantly, we continue to focus on working hand in hand with our customers, adding value for them and the patients that they serve. With that said, I open up for questions.

Operator
16:05 - 16:24

If you wish to ask a question, please dial Pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Sten Gustafsson
16:26 - 16:54

Yeah. Good morning. A couple of questions. First of all, with regards to the ventilator headwinds you had here in Q1, if I remember correctly, you had pretty good. Sales development for ventilators also in Q2 last year. So is it fair to assume that the headwind will continue into Q2? That would be my first question.

Mattias Perjos
16:57 - 17:05

Maybe to some extent, it's not going to be a significant factor, I think, for Q2, but it certainly won't be a big help either.

Sten Gustafsson
17:07 - 17:34

Okay. Excellent. Thank you. My second question is regarding Cardiohelp II two. And what kind of gross margin should we assume for that product compared to the existing Cardiohelp II product? Is it going to be accretive or is it fairly similar gross margins on those two products?

Mattias Perjos
17:35 - 18:01

We don't guide on and disclose Gross Margin levels on any of our products. And Cardiohelp II is no exception. Generally, though, when we work with product development and new launches, we make sure that the products that form the next generation of any therapy or product category have a better gross margin than the generation they replace, and Cardiohelp II should be no exception to this.

Sten Gustafsson
18:02 - 18:31

Okay. Thank you. And one final, if I may, you talk about these lower extraordinary quality costs going forward. Could you please sort of quantify those? We've heard 800 million in the past and where we are today and how low those will be going forward.

Mattias Perjos
18:31 - 18:52

Yeah. I think you're right. We said that they peaked at about 800,000,000 in 2024. We saw a small decrease in 2025. We expect another small decrease this year and then a slightly bigger decrease from 2027 onwards. And the end game here is to at least halve those costs.

Sten Gustafsson
18:55 - 18:56

Excellent. Thank you very much.

Operator
19:00 - 19:04

The next question comes from Erik Caspar from Danske Bank. Please go ahead.

Erik Caspar
19:07 - 19:39

Hello everyone. First I want to get some more color on the decomposition of the ACT decline. Obviously you talked about ventilators, but you're also talking about cardiac assist, etc. . And I think last quarter you said that the demand for cardiac assist was quite positive on the hardware side. So I wanted to ask if something has changed on that side and if you could, if possible, give some more color on how much the Americas segment declined across its different parts.

Mattias Perjos
19:41 - 20:11

No, thanks for the question. We don't dissect the business that much. What I can say on cardiac assist is that we had hoped to be able to resume deliveries in Q1 already of balloon pumps in key markets. And that was not the case. We only got the final approval to start this last Friday. So it will be a Q2 event now. So that's been a little bit of a drag on sales. And also, of course, it has an indirect impact on order intake as well, because customers don't order new pumps unless they have received what they're expecting to be delivered.

Erik Caspar
20:14 - 20:20

Can you say anything about how much the ventilator decline contributed to that 8.5%?

Mattias Perjos
20:20 - 20:26

No, we don't disclose subcategory financial parameters, unfortunately.

Erik Caspar
20:27 - 20:33

But can you say anything if it would have been, say, positive organic growth if it wasn't for ventilators?

Mattias Perjos
20:37 - 20:39

No, I can't answer that either, unfortunately.

Erik Caspar
20:42 - 21:13

All right, fair enough, I had to try. Then on the guidance side, I view it as the wording is a bit softer. Perhaps the visibility is worse now, and maybe you're even seeing a bit more negative outlook. Can you just talk a bit about what you're seeing for the rest of '26 in terms of the customer behavior and dialogues that you're referring to? Has it become slightly more negative or is this just a wording change that I'm dwelling too much on?

Mattias Perjos
21:13 - 21:32

Yeah. No, that was not the intent of the wording change at all. It was really just a way of recognising that we do operate in a rather volatile environment. And we're mindful of that, but we feel confident reconfirming our guidance here, even if the word semantics had changed a little bit.

Erik Caspar
21:34 - 21:55

Okay, just the last question then. Surgical Workflows obviously quite strong. In terms of order intake especially for Americas and digital health, are there some specific projects that these relate to? That sort of makes it nonrecurring or are you seeing a more upbeat environment in the US specifically for Surgical Workflows?

Mattias Perjos
21:56 - 22:32

It's a bit of both. If you look at DHS, it's always lumpy. I mean, they tend to be rather large projects. And we do have that, but there's also a little bit of an underlying better confidence, I think generally in the market. And also I think in the way we operate in this business as well, we made some tweaks to how we organize ourselves, which hopefully also for the long term has a better, more positive impact. But there's absolutely a bit of what I cannot call one-offs, because they're not; it's just project business that is inherently fluctuating by nature.

Erik Caspar
22:34 - 22:45

Okay. Thank you. Can I have one? One short one? Will you tell us anything on the potential impact of the change in steel content tariffs, or is that something you're going to not disclose?

Agneta Palmér
22:46 - 23:06

Yeah. What we can say there is that it's still under analysis how it impacts us. It's fairly recent. But the preliminary evaluation is that if it hits us, it mainly affects components and spare parts, not complete products. And the absolute majority of our exposure is on the complete products.

Erik Caspar
23:08 - 23:12

So the 500 million for full year still holds, do you think.

Agneta Palmér
23:14 - 23:21

I don't think that we have guided on this, but that sounds like a fair assumption given the current levels. Yes.

Erik Caspar
23:23 - 23:25

Okay. Thank you very much. I'll jump back in.

Mattias Perjos
23:25 - 23:26

All right. Thank you.

Operator
23:29 - 23:34

The next question comes from Philip Wetterqvist from SEB Markets. Please go ahead.

Philip Wetterqvist
23:36 - 24:06

Hi. Thank you for taking my questions. I have a couple. First one, given recent price hikes that we are seeing on raw materials such as plastics, steel, aluminum, it seems like you do not see any material effect of this in Q1, and I assume contracts are negotiated a few quarters in advance. But do you anticipate any higher input costs in the coming quarters, or do you not expect any effect at all from this?

Agneta Palmér
24:07 - 24:33

Yes, thank you for that question. If we dissect it a bit into parts, when it comes to freight, which is the more direct near-term impact, we have very limited impact in Q1. But if it's prolonged, yes, there will be some impact in Q2 onwards. When it comes to plastics, etc. It's too early to say that we have any effects there.

Philip Wetterqvist
24:36 - 25:01

Okay. Thank you. And at the Q4 call, you indicated price increases of around 2% for 2026. Did that materialize here in Q1, meaning the 0.8% organic growth was hampered by lower volumes, or are you able to accelerate price increases further if you see increasing costs here in the coming quarters?

Agneta Palmér
25:02 - 25:15

We still stand by that roughly 2%. It is a gradual rollout during the year. So it's slightly less than that in Q1. But we are progressing well towards that level.

Philip Wetterqvist
25:17 - 25:31

Okay. But let's say we see increasing costs. So if costs are increasing, you won't be able to translate that onwards to your customers. You still anticipate only 2% price increase.

Agneta Palmér
25:31 - 25:59

Then this is always an ongoing discussion that we have with the commercial dynamics and the cost levels that we have. So of course, we will adapt our ways of working if we see that we get higher inflation, but it's not an automatic or something that we can directly pass on. And Matthias mentioned it for tariffs. And it's similar then for raw material. But we do have very active pricing.

Philip Wetterqvist
26:02 - 26:05

Okay. Thank you. I'll jump back into the queue.

Operator
26:08 - 26:13

The next question comes from Kristofer Lilleberg from DNB Carnegie. Please go ahead.

Unknown 1
26:15 - 26:56

Thank you. I have a few short ones. That's okay. First of all, is it possible to quantify at all the positive effect you expect here from the new ECMO approval in Europe, or whether that potential positive effect is more a factor of when you get the US approval again. And then could you just clarify a little bit about the Cardiohelp II status here in Europe and the US filing and then finally on tariffs, if it's fair to assume a really neutral effect here year over year from the second quarter. Thank you.

Mattias Perjos
26:58 - 27:30

Yeah. I think we can't quantify. But of course there is a positive effect from the launch of Cardiohelp II. This is an important part of our product range. So definitely a net positive. But I can't give you a magnitude of that when it comes to the CardioSave status. We got approval to start shipping last Friday. So the first pumps are being delivered in key markets this week, and the US filing status. There is no change here. We still expect to do that before the half year mark.

Agneta Palmér
27:33 - 27:48

And then when it comes to tariffs, it's dependent, obviously, on the tariff level, but also on the product mix of imports. But generally speaking, yes, it sounds like a fair assumption.

Unknown 1
27:50 - 27:51

Great. Thank you so much.

Mattias Perjos
27:52 - 27:53

Thank you.

Operator
27:54 - 28:07

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from David Adlington from JP Morgan. Please go ahead.

David Adlington
28:10 - 28:31

Could you quantify the impact of foreign exchange hedges in Q1, and how they roll off through the next 12 months or so? And then secondly, obviously we're a quarter in now. Still no margin guidance. Just wondering if you're willing to give us some idea of how you're seeing margins for the year, whether up or down or sideways. Thank you.

Agneta Palmér
28:33 - 29:11

If we start with FX, we have not changed anything specifically regarding our hedging strategy. We will not disclose that. But just a reminder, I think we have talked about it on this call before. Looking at the natural hedge, around 60% of what we sell in the US. We also produce in the US. And then the second thing maybe to mention regarding natural hedging and FX exposure is that we work very actively with our payment flows to compensate or offset as much as possible. Those are the two things to highlight there. But no quantification of hedging effects as such.

Mattias Perjos
29:15 - 29:32

And on the margin guidance, there's still. As stated in the presentation. We are confident about the long term margin guidance of 16 to 19%.

David Adlington
29:35 - 29:41

Sorry, you broke up again. I missed the first part of that. Would you mind just repeating the margins for this year?

Mattias Perjos
29:41 - 30:00

Yeah, I just said that, as you know, there's a lot of uncertainty in the world, so we're not going to do any margin guidance for 2026. We remain with the top line guidance only, and we remain with the long term margin guidance of 16 to 19%.

David Adlington
30:02 - 30:03

Thank you.

Operator
30:11 - 30:15

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Unknown 1
30:17 - 30:44

Yes. Hi. I just have a follow-up on Acute Care Therapies; ECLS consumables continued to grow despite being up against a rather tough comparison base, and I assume there were some flu-related headwinds here given the lower hospitalisations. Q1 2026. So I just wonder if there were any one-offs or stockings of consumables that you saw here in the quarter or if it's rather the underlying run rate.

Mattias Perjos
30:45 - 30:50

You broke up for a second. Can you repeat the question on the ECLS consumables, please?

Unknown 1
30:51 - 31:04

Yes. So it seems pretty strong considering the quite tough comparison. So I just wonder if you saw any stockings or one-offs here in the quarter or if it rather reflects the underlying run rate.

Mattias Perjos
31:04 - 31:13

No, there were no abnormal events in Q1. I think your analysis of this seems correct. It's a good underlying demand.

Unknown 1
31:15 - 31:23

Yeah. Okay. And can you just confirm that flu-related sales were lower this quarter versus Q1 2025.

Mattias Perjos
31:25 - 31:36

And that we see the same flu data as you when it comes to hospitalizations? How customers use the products they buy, whether it's for treating flu or something else, we don't have perfect insight into.

Unknown 1
31:38 - 31:41

Okay. Fair enough. Thanks. I'll jump back into the queue.

Mattias Perjos
31:41 - 31:41

Thank you.

Operator
31:47 - 32:04

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Mattias Perjos
32:06 - 32:15

Okay. Thank you very much. I think I already made the summary before the Q&A, so just wanted to say thanks everyone for joining and I wish you a good rest of the day. Thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…